Vanguard Fiduciary Trust
GALT icon

Vanguard Fiduciary Trust’s Galectin Therapeutics GALT Stock Holding History

Vanguard Fiduciary Trust’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Buy
366,476
+62,235
+20% +$161K ﹤0.01% 2756
2026
Q1 		$849K Buy
+304,241
New +$925K ﹤0.01% 3000

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust's GALT Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Galectin Therapeutics (GALT) stake by 20% in Q2 2026, buying an estimated $161K and bringing the position to 366,476 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2756.

Vanguard Fiduciary Trust first reported a position in GALT in Q1 2026 and has held it in 2 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Vanguard Fiduciary Trust held 366,476 shares of Galectin Therapeutics worth $1.7M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 62,235 Galectin Therapeutics shares in Q2 2026, an estimated $161K.
  • Galectin Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2756 holding.
  • Vanguard Fiduciary Trust first reported a position in Galectin Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.